Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Checkmate Pharmaceuticals Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Nov 5, 2024
Management Tracks
Alan Bash named president of Carvykti at Legend
Plus: CureVac hires Axel Malkomes as CFO; new CEOs at Coya, Libra; and updates from 4BIO, Memo and Alltrna
BioCentury | Jun 19, 2024
Management Tracks
Seaport adds Loebel as CMO, Gladstein as general counsel
Plus: SpyBiotech names Keith Dewedoff CFO, and updates from Kriya, CytomX and Progentec
BioCentury | Mar 12, 2024
Management Tracks
Hyku names Kleem Chaudhary CEO
Plus: Jones hired as CBO at MOMA, and updates from Metrion, OPPI, 4BIO and Quotient
BioCentury | Dec 5, 2023
Management Tracks
Glucksmann at the helm at Sensorium
Plus: CEO, CMO out at Theseus and updates from Zenas, Nanoscope, Immunitas and more
BioCentury | Jan 4, 2023
Management Tracks
Ex-Checkmate CEO Bash to lead ZielBio
Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
BioCentury | Nov 3, 2022
Management Tracks
Fantaccini becomes head of medical affairs, CSO at Novartis
Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra
BioCentury | Jun 2, 2022
Deals
Seeking more control over combos, Regeneron retakes full rights to cancer ‘backbone’ Libtayo
Biotech buys out Sanofi’s share of profits from PD-1 inhibitor, sees drug as ‘centerpiece’ in oncology growth
BioCentury | Apr 19, 2022
Deals
Regeneron makes closing move on Checkmate, gaining cancer program in $250M deal
Regeneron adds partner Checkmate’s clinical TLR9 program via high-premium takeout, with stock near all-time low
BioCentury | Oct 28, 2021
Management Tracks
Labinger out as Checkmate CEO
Plus: Travecta, MTS Health Partners, Elevar and Y Combinator
BioCentury | Sep 3, 2021
Management Tracks
Civetta picks Roberts as CEO
Plus, management moves at Crinetics, OraSure, Silence, Avacta, Oncternal and more
Items per page:
1 - 10 of 40